Immunomodulatory drugs in chronic lymphocytic leukemia: A new treatment paradigm

Leukemia and Lymphoma

Volumn 48, Issue 5, 2007, Pages 866-869

  Molica, Stefano ^a  

^a Medical Oncology Unit   (Italy)

Author keywords

Anti angiogenesis; CLL; Lenalidomide; Thalidomide

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; FLUDARABINE; IMMUNOMODULATING AGENT; LENALIDOMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; RECOMBINANT ERYTHROPOIETIN; THALIDOMIDE;

ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; CANCER RELAPSE; CARCINOGENESIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; FEBRILE NEUTROPENIA; HEMATOLOGIC DISEASE; HUMAN; IMMUNOMODULATION; LOW DRUG DOSE; MONOTHERAPY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NEUROLOGIC DISEASE; NEUROTOXICITY; PRIORITY JOURNAL; REVIEW; SALVAGE THERAPY; SEDATION; SIDE EFFECT; TERATOGENESIS; TUMOR FLARE; TUMOR LYSIS SYNDROME;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; HUMANS; IMMUNOLOGIC FACTORS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; REMISSION INDUCTION; THALIDOMIDE; TREATMENT OUTCOME;

EID: 34547468130     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190601126636     Document Type: Review

References (25)

1. Chiorazzi, N., Rai, K. R. and Ferrarini, M. (2005) Chronic lymphocytic leukemia. N Engl J Med, 352, pp. 804-815.
2. Kay, N. E., Bone, N. D., Tschumper, R. C., Howell, K. H., Geyer, S. M. and Dewald, G. W. (2002) B-CLL cells are capable of synthesis and secretion of both pro-and anti-angiogenic molecules. Leukemia, 16, pp. 911-916.
3. Kay, N. E., Jelinek, D. F. and Dewald, G. W. (2002) Progression events in B-chronic lymphocytic leukemia. Hematology, pp. 197-203.
4. Novak, A. J., Bram, R. J., Kay, N. E. and Jelinek, D. F. (2002) Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukaemia cells: A mechanism for survival. Blood, 100, pp. 2973-2979.
5. Chanan-Khan, A. and Porter, C. W. (2006) Immunomodulating drugs for chronic lymphocytic leukemia. Lancet Oncol, 7, pp. 480-488.
6. Yagyu, T., Kobayashi, H., Matsuzaki, H., Wakahara, K., Kondo, T. and Kurita, N. (2005) Thalidomide inhibits tumor necrosis factor-alpha-induced interleukin-8 expression in endometriotic stromal cells, possibly through suppression of nuclear factor-kappa B activation. J Clin Endocrinol Metab, 90, pp. 3017-3021.
7. Liu, X., Wang, J., Wang, Z., Jiang, W. and Reed, E. (2003) Thalidomide down-regulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells. Anticancer Res, 23, pp. 2481-2487.
8. Raje, N. and Anderson, K. C. (2002) Thalidomide and immunomodulatory, drugs as cancer therapy. Curr Opin Oncol, 14, pp. 635-640.
9. Davies, F. E., Raje, N., Hideshima, T., Lentzsch, S., Young, G. and Tai, Y. T. (2001) Thalidomide and immunomodulatory derivatives augment natural killer cell cytoxicity in multiple myeloma. Blood, 98, pp. 210-216.
10. Dredge, K., Marriott, J. B. and Dalgleish, A. G. (2002) Immunological effects of thalidomide and its chemical and functional analogs. Crit Rev Immunol, 22, pp. 425-437.
11. Chanan-Khan, A., Padmanabhan, S., Miller, K., Pera, P., DiMiceli, L. and Ersing, N. (2005) In vivo evaluation of immunomodulating effects of lenalidomide on tumor cell microenvironment a possible underlying mechanism of antitumor effects observed in patients with chronic lymphocytic leukemia. Blood, 106, p. 834a.
12. Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P. and Eddlemon, P. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med, 341, pp. 1565-1571.
13. Folkman, J., Rogers, M. S., Barlogie, B., Shaughnessy, J. and Tricot, G. (2006) Thalidomide for multiple myeloma. N Engl J Med, 354, pp. 2389-2390.
14. Raza, A., Meyer, P., Dutt, D., Zorat, F., Lisak, L. and Nascimben, F. (2001) Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood, 98, pp. 958-965.
15. Kay, N., Geyer, S., Yaqoob, I., Phyliky, R., Kutteh, L. and Li, C. Y. (2003) Thalidomide treatment in chronic lymphocytic leukemia: A North Central Cancer Treatment Group (NCCTG) study. Blood, 102, p. 359b.
16. Chanan-Khan, A., Miller, K. C., Takeshita, K., Koryzna, A., Donohue, K. and Bernstein, Z. P. (2005) Result of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL). Blood, 106, pp. 3348-3352.
17. Chanan-Khan, A., Miller, K. C., Musial, L., Lawrence, D., Padmanabhan, S. and Takeshita, K. (2006) Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol, 24, pp. 5343-5349.
18. Furman, R. R., Leonard, J. P., Allen, S. L., Coleman, M., Rosenthal, T. and Gabrilore, J. L. (2005) Thalidomide alone or in combination with fludarabine are effective treatment for patients with fludarabine-relapsed and refractory CLL. Proc AM Soc Clin Oncol, p. 6640.
19. Trompeter, S., Yong, K., Jewell, A. and Nathwani, A. Thalidomide in combination with dexamethasone and cyclophosphamide shows activity in patients with relapsed chronic lymphocytic leukemia. 11th International Workshop on Chronic Lymphocytic Leukemia Brooklyn, NY, USAp. 88.
20. List, A., Kurtin, S., Roe, D. J., Buresh, A., Mahadevan, D. and Fuchs, D. (2005) Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med, 352, pp. 549-557.
21. Richardson, P. G., Schlossman, R. L., Weller, E., Hideshima, T., Mitsiades, C. and Davies, F. (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood, 100, pp. 3063-3067.
22. Mitsiades, C. S. and Mitsiades, N. (2004) CC-5013 (Celgene). Curr Opin Investig Drugs, 5, pp. 635-647.
23. Miller, K., Czuczman, M. S. and Dimiceli, L. (2006) Lenalidomide (L) induces high response rates with molecular remission in patients (pts) with relapsed (rel) or refractory (ref) chronic lymphocytic leukemia (CLL). Proc Am Soc Clin Oncol, p. 6517.
24. DiMiceli, L., Miller, K., Rickert, M., Wallace, P., Marshall, P. and DePaolo, P. (2005) Characterization of IMiDs (immunomodulating agents) induced flare reaction in patients with chronic lymphocytic leukemia (CLL) and correlation with changes in serum cytokine levels. Blood, 106, p. 344b.
25. Molica, S., Vacca, A., Mirabelli, R., Ria, R. and Ribatti, D. (2006) Angiogenesis in chronic lymphocytic leukemia: An emerging target. Clin Leukemia, 2, pp. 118-122.